Endocrine therapy News (1 article)
Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need
Trial stopped early after positive interim results showed everolimus plus exemestane extended time without tumor growth Postmenopausal ER+HER2- metastatic breast cancer patients whose disease has progressed despite initial endocrine therapy need effective new...
Published on 5 July 2011, 14:27
We have launched our peer- reviewed, Open-access journal: Insciences Journal